BioWorld® - Medical Device Daily

BioWorld Industrial Biotechnology StatReport: Immediate and Comprehensive Industry Information
Nonclinical development (Basel, Nutley, NJ)
Diagnostics:
Clinical chemistry, immunology, hematology, molecular diagnostics (PCR),
diagnostic equipment
PRODUCTS ON MARKET: Pharmaceutical specialties:
Antibacterials (Bactrim, Rocephin, Globocef)
Anticancer drugs (Roferon-A, Furtulon, Xeloda, Vesanoid, Mabthera)
Antidepressants (Aurorix)
Antiepileptic (Rivotril)
Antifungals (Loceryl)
Antimalarials (Fansidar, Lariam, Fansimef)
Antiparkinsonian (Madopar, Tasmar)
Antirheumatic, pain (Tilcotil, Naprosyn/Aneprox, Toradol)
Antivirals (Roferon-A, Hivid, Invirase/Fotovase, Viracept,
Cymevene/Cytovene)
Anxiolytics (Valium Roche, Lexotan, Nobrium, Librium)
Hypnotics and anesthetics (Dormicum/Versed, Rohypnol,
Dalmadorm/Dalmane)
Benzodiazepine antagonist (Anexate, Romazicon)
Cardiovascular (Inhibace, Ticlid, Cardene, Coreg, Dilatrend, Reteplase)
Dermatologicals (Accutane/Roaccutane, Tigason, Neotigason)
Hematological drugs (Neupogen, Recormon)
Immunosuppressant (Cellcept, Zenapax)
Metabolic drugs (Xenical, Rocaltrol, Euglucon, Cedur)
Others (Pulmozyme)
OTC drugs: vitamins, analgesics, antacids
FibroGen Inc.
225 Gateway Boulevard
South San Francisco CA 94080, US
Phone: (650) 866-7200; Fax: (650) 866-7201
Web: www.fibrogen.com; E-mail: info@fibrogen.com
KEY PERSONNEL: Thomas B. Neff; Chairman and CEO
Russell H. Ellison; VP, Clinical Development
William Hodder; VP, Business Development
Wilbert Lee; VP, CFO and Treasurer
David Y. Liu, Ph.D.; VP, Research
Claire J. Lockey; VP, Regulatory Affairs
Tim C. Opler; VP, Strategy
James W. Polarek, Ph.D.; VP, Collagen and Gelatin Development
Leanne C. Price; VP, Intellectual Property
David A. Yeowell, Ph.D.; VP, Product Development
EMPLOYEES: 130 employees
HISTORY: Incorporated in September 1993
Began R&D operations in 1994
FACILITIES: FibroGen Inc.--South San Francisco, Calif. (Headquarters, R&D)
FibroGen Europe Corp.--Helsinki, Finland (R&D)
STOCK-FINANCIAL HISTORY: Privately held
PRIVATE PLACEMENTS: 5 offerings totalling $94.1M (through 9/00)
Raised $100M from placement of convertible preferred stock (2/05)
FibroGen Europe Ltd.--2 offerings totalling $13.5M
SUBSIDIARIES/DIVISIONS: FibroGen Europe Corp.
Tukholmankatu 8 B (Biomedicum II)
FIN-00290 Helsinki Finland
Phone: +358 9 56 373 220
Fax: +358 9 56 373 224
Copyright ©2006 AHC Media ® 163